Berapakah harga Paion AG (PA8)

Harga Paion AG (PA8) adalah $0.42701586

Apakah topi pasaran Paion AG (PA8)

Cap pasaran Paion AG (PA8) adalah $3.21M

Paion AG (PA8) Hasil Dividen

Paion AG is a specialized pharmaceutical firm engaged in the global development and commercialization of medicines for hospital settings, specifically addressing needs in sedation, anesthesia, and critical care. Its primary compound, Remimazolam, is an ultra-short-acting intravenous benzodiazepine designed as a sedative/anesthetic, currently progressing through clinical trials for applications in procedural sedation, general anesthesia, and intensive care unit sedation. The company's pipeline also includes Angiotensin II, a vasoconstrictor for treating severe low blood pressure in adults experiencing septic or other forms of distributive shock, and Eravacycline, a new fluorocycline antibiotic targeting complex intra-abdominal infections in adults. Paion AG collaborates with various partners through licensing and strategic agreements, including Cosmo Pharmaceuticals, Wuhan Humanwell Innovative Drug Research and Development Center Limited Company, Hana Pharm, Yichang Humanwell, and Mundipharma. Established in 2000, Paion AG operates from Aachen, Germany.

Tahun	Hasil Dividen	Ubah
Tidak cukup data untuk tarikh yang disediakan.

Tahun

Hasil Dividen

Ubah

Tidak cukup data untuk tarikh yang disediakan.

Syarikat	Hasil Dividen	Negara
MERCK Kommanditgesellschaft auf Aktien MER.SW	0.00%	DE
Merck KGaA MRK.DE	0.00%	DE
Takeda Pharmaceutical Company Limited 4502.T	0.00%	JP
Galderma Group AG GALD.SW	0.00%	CH
Sun Pharmaceutical Industries Limited SUNPHARMA.NS	0.83%	IN

Syarikat

Hasil Dividen

Negara